Comprehending COVID-19: Analytical Science in the Context of COVID-19

Significance of the Topic

Analytical methods such as liquid chromatography (LC) and mass spectrometry-based LC-MS play a pivotal role in accelerating the development and quality control of COVID-19 diagnostics, vaccines, and therapeutics. Reliable characterization of biomolecules and small-molecule drugs ensures safety, efficacy, and regulatory compliance across multiple application areas.

Objectives and Study Overview

This application note surveys how LC and LC-MS technologies support five critical areas in the COVID-19 response: protein-based vaccines, PCR diagnostics, monoclonal antibodies, RNA/DNA vaccines, and small-molecule therapies. It highlights collaborative efforts by Waters Corporation’s COVID-19 Innovation Response Team and directs readers to specialized resources for detailed protocols.

Methodology and Instrumentation

High-performance LC and advanced LC-MS platforms enable robust analysis of proteins, nucleic acids, and small molecules. Key techniques include peptide mapping, intact mass analysis, glycan profiling, oligonucleotide purity assessment, and bioanalysis of drug candidates.

Used Instrumentation

• SYNAPT XS Mass Spectrometer
• BioAccord LC-MS System
• BioResolve SCX mAb Column
• IonHance CX-MS pH Concentrates
• Reversed-Phase and Size-Exclusion LC Modules

Key Results and Discussion

Protein-Based Vaccines:
• LC-MS characterization of recombinant spike protein ensures accurate glycosylation profiling, peptide mapping, and intact mass confirmation.

PCR-Based Diagnostics:
• LC and LC-MS verify the identity and purity of primers and probes, supporting reliable detection of viral RNA.

Monoclonal Antibodies:
• Charge variant analysis, higher-order structure assessment, and glycan profiling via LC-MS guide mAb development for neutralization and cytokine modulation.

RNA/DNA Vaccines:
• Enzymatic digestion of synthetic mRNA/DNA followed by LC-MS fragment analysis confirms sequence integrity and quantifies impurities such as SNPs; intact mass workflows assess capping efficiency.

Small-Molecule Therapies:
• LC and LC-MS facilitate release testing, formulation studies, bioanalysis, and therapeutic drug monitoring for repurposed drugs and novel inhibitors.

Benefits and Practical Applications

• Ensures critical quality attributes of vaccines and biologics.
• Validates oligonucleotide-based diagnostic reagents.
• Supports rapid scale-up and regulatory filing of therapeutics.
• Delivers high sensitivity and specificity for complex biomolecular analyses.

Future Trends and Opportunities

• Integration of native MS and ion mobility for structural insights.
• Automation and high-throughput workflows to meet pandemic-scale demands.
• AI-driven data interpretation and predictive analytics.
• Point-of-care MS systems for decentralized diagnostics.

Conclusion

LC and LC-MS technologies have been instrumental in addressing analytical challenges throughout the COVID-19 response, driving vaccine development, diagnostics, and therapeutic monitoring. Continued innovation in instrumentation and workflows will further strengthen global preparedness for emerging infectious diseases.

References

• Rapid and Sensitive Characterization of N-Glycans from SARS-CoV-2 Spike Protein, 720006914EN
• Preliminary Examination of the SARS-CoV-2 Spike Protein by Peptide Mapping, 720006909EN
• Reversed-Phase Liquid Chromatography of Intact SARS-CoV-2 Spike Protein, 720006907EN
• Enhanced Performance of the SYNAPT XS for HDX MS Data Quality, 720006870EN
• Online IEX-MS of mAb Charge Variants Using BioResolve SCX, IonHance CX-MS, and BioAccord, 720006672EN